Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.73 |
| ▸ | KDR | P35968 | 3/20 | 0.68 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.67 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.66 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.66 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.66 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.66 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.66 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.66 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.66 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.66 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 0.66 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 0.66 |
| ▸ | AURKA | O14965 | 1/20 | 0.63 |
| ▸ | INSR | P06213 | 1/20 | 0.63 |
| ▸ | FBP1 | P09467 | 1/20 | 0.63 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.63 |
| ▸ | FLT4 | P35916 | 1/20 | 0.63 |
| ▸ | CLK1 | P49759 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL643027 | 0.89 | EGFR (0.79) | EGFRKDRERBB2HDAC3HDAC4 | |
| SCHEMBL643422 | 0.87 | EGFR (0.79) | EGFRKDRERBB2HDAC3HDAC4 | |
| SCHEMBL641806 | 0.87 | EGFR (0.79) | EGFRKDRERBB2HDAC3HDAC4 | |
| SCHEMBL4342528 | 0.87 | EGFR (0.79) | EGFRKDRERBB2HDAC3HDAC4 | |
| SCHEMBL641952 | 0.86 | EGFR (0.73) | EGFRKDRERBB2HDAC3HDAC4 | |
| SCHEMBL7224798 | 0.86 | EGFR (0.70) | EGFRKDRERBB2HDAC3HDAC4 | |
| SCHEMBL2102985 | 0.85 | EGFR (1.00) | EGFRKDRERBB2AURKAINSR | |
| SCHEMBL17520337 | 0.85 | EGFR (1.00) | EGFRKDRERBB2AURKAINSR | |
| SCHEMBL20305537 | 0.85 | EGFR (0.70) | EGFRKDRERBB2HDAC3HDAC4 | |
| SCHEMBL18435103 | 0.84 | EGFR (0.90) | EGFRKDRERBB2AURKAINSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203683-A1 | BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, THEIR USE, AND PROCESSES FOR PREPARING THEM | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-08-13 | — | — | US | disclosed |
| US-20060063752-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-03-23 | — | — | US | disclosed |
| EP-1163227-B1 | BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, AND PROCESSES FOR PREPARING THEM | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203683-A1 | BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, THEIR USE, AND PROCESSES FOR PREPARING THEM | REN, APC, PKD1 | EGFR 2063/4885KDR 3805/4885ERBB2 3690/4885 |
| US-20060063752-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | REN, APC, PKD1 | EGFR 2063/4885KDR 3805/4885ERBB2 3690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.